Fanconi anemia group A protein (FANCA)

Fanconi anemia group A protein (FANCA) is a core component of the Fanconi anemia (FA) DNA repair pathway, essential for the repair of interstrand crosslinks during DNA replication[3][4]. Approximately 60% of patients with Fanconi anemia—a rare blood disorder characterized by bone marrow failure, congenital abnormalities, and increased cancer risk—have mutations in the FANCA gene[2]. FANCA is a large nuclear protein, typically acting as part of a multi-protein core complex with others such as FANCC, FANCG, FANCL, and associated factors[3]. The FA core complex is necessary for the monoubiquitination of FANCD2 and FANCI, initiating DNA repair at stalled replication forks[3][4]. The C-terminal domain of FANCA mediates binding to both DNA and RNA—preferentially to single-stranded nucleic acids and specific structures such as 5′-flap or tail DNA—with most disease-causing mutations clustering in this region[2][4]. FANCA also participates in broader cellular processes, including regulation of gene expression and cell cycle, and potentially in RNA metabolism[2]. Dysfunction or mutation in FANCA leads to cellular hypersensitivity to DNA crosslinking agents and genomic instability, underpinning the pathogenesis of Fanconi anemia and its associated malignancy risk[3][4]. There are currently no approved drugs targeting FANCA itself, but its functional status is a key diagnostic biomarker for Fanconi anemia and may inform cancer risk[2][3].

Other names

Fanconi anemia complementation group AFANCAFAAFACAFANCHProtein FACAFA-HFAHFA1Fanconi anemia, type 1Fanconi anemia complementation group H

Not directly targeted by approved drugs; its mechanism relates to being part of a complex that facilitates monoubiquitination of FANCD2, leading to DNA interstrand crosslink repair